Effect of cefamandole nafate on blood coagulation and platelet function

Custer, Galen; Briggs, Brittany; Smith, Richard

doi:10.1128/aac.16.6.869

Cited by 17 publications

(4 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous clinical evaluations of ceftazidime have been reported in the therapy of varied infections in a few patients each (3,6,22,23). Although ceftazidime would not be considered a first-line drug for the therapy of community-acquired pneumonia, a clinical trial was designed to compare the efficacy and safety of ceftazidime to cefamandole in the treatment of such pneumonias, with particular attention directed toward secondary coagulation abnormalities (1,4,7,31) and the development of resistance during therapy (24)(25)(26)(27).…”

mentioning

confidence: 99%

Comparison of ceftazidime with cefamandole for therapy of community-acquired pneumonia

Engle¹,

Lifland²,

Schleupner³

1985

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Ceftazidime and cefamandole were compared in the treatment of pneumonia. The median MIC of ceftazidime for all Streptococcus pneumoniae (n = 17) and Haemophilus influenzae (n = 10) isolates was 0.125 ,ug/ml. All other isolates were inhibited by <0.5 ,Ig of ceftazidime per ml, with the exception of a group B streptococcus (MIC = 4 ,ug/mI). Satisfactory clinical responses were observed in 91% (20 of 22) of cefamandole-treated patients and 85% (17 of 20) of ceftazidime-treated patients.

show abstract

mentioning

confidence: 99%

Comparison of ceftazidime with cefamandole for therapy of community-acquired pneumonia

Engle¹,

Lifland²,

Schleupner³

1985

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…The impact that therapeutic antibacterials have upon the coagulation profile has been previously described, albeit largely in patients without hematologic malignancies. Prolongation of both the PT and PTT is shown to occur in a dose and time-dependent manner [16]. One study demonstrated that as few as seven consecutive days of intravenous cephalosporin administration can prolong the PT, although this did not translate into a higher rate of bleeding [17].…”

Section: Discussionmentioning

confidence: 99%

Impact of Prophylactic Antibacterials on Coagulation Profiles and Bleeding in Patients with Acute Myeloid Leukemia/Myelodysplastic Syndrome

Allen¹,

Gautam²,

Cheng³

et al. 2023

Acta Haematol

View full text Add to dashboard Cite

Patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) often receive antibacterial prophylaxis. Antibacterial agents can cause elevations in the prothrombin time and international normalized ratio (INR). The impact of prophylactic antibacterials on the coagulation profiles and bleeding risk in patients with AML/MDS is unknown. We evaluated patients with AML or MDS who were being admitted to the hospital. The cohort was divided into two groups of patients: (1) those receiving and (2) those not receiving prophylactic antibacterials, at the time of admission. We conducted a retrospective cohort study of adult patients with AML/MDS admitted to Yale-New Haven Hospital between 2015–2019. The study was approved by the Yale Institutional Review Board. Inclusion criteria included patients >18 years old with a diagnosis of AML or MDS admitted to the hospital. We identified 150 individual patient encounters with active AML/MDS admitted to Yale-New Haven of which 32 occurred while on and 118 while off antibacterial prophylaxis. Median duration of pre-admission antibacterial exposure was 2 (range: 0.07–24) months. Patients on antibacterial prophylaxis had higher INR (median 1.14 vs. 1.03, p = 0.0002), and higher partial thromboplastin time prolongation (median 26.5 vs. 24.3, p < 0.0014), than patients without antibacterial prophylaxis. Patients without antibacterial prophylaxis had higher rates of bleeding using the ISTH-defined criteria (24.6% vs. 6.3%, p = 0.043), including higher rates of ISTH major (2 vs. 0) and clinically relevant bleeding (9 vs. 0). Patients with AML/MDS on antibacterial prophylaxis were more likely to have an abnormal coagulation profile when compared with their counterparts not on prophylaxis. Conversely, rates of bleeding were higher in patients not on prophylaxis. These data suggest that prophylactic antibacterials do not increase bleeding risk in patients with AML/MDS.

show abstract

“…DISCUSSION Antibiotic-induced platelet dysfunction has been reported most frequently with carbenicillin and penicillin (2,4). However, other penicillins and some cephalosporins, including a few of the newer agents (e.g., piperacillin and moxalactam), have been shown to produce platelet dys- function at various concentrations (3,6,8,13,14). The cases presented here suggest that nafcillin can also induce a hemostatic defect attributable to platelet dysfunction.…”

mentioning

confidence: 88%

Nafcillin-induced platelet dysfunction and bleeding

Alexander¹,

Russo²,

Fohrman³

et al. 1983

Antimicrob Agents Chemother

View full text Add to dashboard Cite

This paper describes two cases of nafcillin-induced platelet dysfunction, with positive rechallenge data for one patient. Nafcillin resulted in abnormal bleeding times in both patients and a clinically apparent bleeding episode in one of the cases. Platelet function tests were performed on one patient during the initial therapy and after rechallenge with nafcillin. Platelet aggregation showed abnormal responses to ADP, collagen, and epinephrine. Platelet count and morphology were normal. Nafcillin should be recognized as another antibiotic which causes platelet function abnormalities and clinical bleeding episodes. sites, but the hematocrit did not decrease. At this time, debridement with possible grafting was planned for the leg ulcers. The preoperative laboratory screen revealed a template bleeding time of greater than 25 min (normal, 6 to 9 min), and the procedure was cancelled. The partial thromboplastin time and platelet count were normal. Platelet morphology was also normal. The prothrombin time was 15.6 s with a control of 13.6 s and was corrected with normal plasma. Liver function tests were normal, although 1 week earlier mild elevations of serum glutamic oxalacetic transaminase and serum glutamic pyruvic transaminase had been present. The patient's medications included prednisone (40 mg daily), double-strength trimethoprim-sulfamethoxazole (twice daily), sulindac (Clinoril; 200 mg twice daily), amitriptyline (50 mg at bedtime), and nafcillin as described above. All medications except prednisone and nafcillin were discontinued, and the bleeding time was repeated at 48 and 72 h. Platelet function tests revealed abnormal aggregation (see Table 1). Surgery was deferred, nafcillin was discontinued, and the patient was discharged. A bleeding time repeated 9 days later was normal (6.5 min).The patient was readmitted 1 month later for surgical repair of the extensor tendons on the right hand. The only medication at that time was prednisone (30 mg daily). The platelet count, prothrombin time, and partial thromboplastin time were normal, and the bleeding time was 6.5 min. The tendon repair was accomplished without excessive bleeding, and consent of the patient to rechallenge her with nafcillin was obtained. During this period, fat-containing foods were not allowed after 10 p.m., to prevent lipemic blood samples. No blood samples were drawn other than those done for coagulation 59

show abstract

Effect of cefamandole nafate on blood coagulation and platelet function

Cited by 17 publications

References 11 publications

Comparison of ceftazidime with cefamandole for therapy of community-acquired pneumonia

Comparison of ceftazidime with cefamandole for therapy of community-acquired pneumonia

Impact of Prophylactic Antibacterials on Coagulation Profiles and Bleeding in Patients with Acute Myeloid Leukemia/Myelodysplastic Syndrome

Nafcillin-induced platelet dysfunction and bleeding

Contact Info

Product

Resources

About